Equity Profile

ROIV

Roivant Sciences Ltd.

Health CareBiotechnology$24.8B

Aug10Mon

Pre-Earnings Brief

UpcomingQ1-2026Pre-Market9:00 AM EDT

Company Snapshot

Roivant Sciences Ltd. is a biotechnology company focused on advancing innovative medicines and therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's market performance and ability to scale its operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ROIV Q1-2026 Earnings Preview

Context

Company Snapshot

Roivant Sciences Ltd. is a biotechnology company focused on advancing innovative medicines and therapies. Operating in the healthcare sector, Roivant aims to improve patient outcomes through its unique approach to drug development and commercialization.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+61.93%

Avg Stock Reaction

+5.96%

Last Quarter Recap

In the last quarter, Roivant reported an EPS of $0.28, significantly beating expectations. The stock reacted positively, gaining nearly 15% the following day.

Management Promises & Guidance

Continued focus on advancing clinical trials for key therapies.
Commitment to enhancing operational efficiency.
Plans to expand partnerships with other biotech firms.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Roivant's upcoming earnings report, given its recent performance. The market is looking for continued improvement in EPS and revenue growth.

Bull Case

If Roivant can maintain its trend of beating EPS estimates, it could see a strong positive reaction from investors, reinforcing confidence in its growth strategy.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a negative market reaction, especially given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q1-2026?

The EPS figure is crucial for understanding Roivant's profitability and will heavily influence investor sentiment.

How much has R&D spending increased compared to last quarter?

R&D spending is a key indicator of Roivant's commitment to innovation and future growth potential, making it a focal point for investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Roivant's potential for strong EPS growth based on its recent performance and R&D advancements.

Supporting Evidence

Roivant has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.

The options market is pricing a significant move, suggesting that investors are anticipating volatility that could favor a positive outcome.

Key Risk

If R&D spending shows a marked increase without corresponding revenue growth, it could undermine the bullish consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Roivant's ability to sustain its recent performance, particularly in terms of profitability and growth.

Bull Confirmed If

An EPS of $0.30 or higher would confirm the bullish outlook and suggest strong operational performance.

Bear Confirmed If

An EPS below $0.20 would indicate potential issues with profitability and could confirm the bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±10.0%

Historical Avg

±7.2%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating uncertainty about the earnings outcome.

Options are pricing ±10.0% while ROIV has averaged ±7.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

51.6%

Calls (5K)P/C Ratio: 0.18Puts (1K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Roivant beats expectations, history suggests a potential stock increase of around 9.09%, confirming investor confidence in its growth strategy.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction, reflecting cautious optimism without strong conviction.

Miss

If Roivant misses estimates, the stock could decline, with historical data suggesting an average drop of around 0.73%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of ongoing clinical trials.
2Details on any new partnerships or collaborations.
3Insights into R&D spending and its impact on future growth.
4Management's outlook on market conditions and competition.
5Any changes in guidance or strategic direction.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug7

PAABMO

Plains All American Pipeline, L.P.

PreviewView

Aug7

ESNTBMO

Company Snapshot

Roivant Sciences Ltd. is a biotechnology company focused on advancing innovative medicines and therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's market performance and ability to scale its operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ROIV Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+61.93%

Avg Stock Reaction

+5.96%

Last Quarter Recap

In the last quarter, Roivant reported an EPS of $0.28, significantly beating expectations. The stock reacted positively, gaining nearly 15% the following day.

Management Promises & Guidance

Continued focus on advancing clinical trials for key therapies.
Commitment to enhancing operational efficiency.
Plans to expand partnerships with other biotech firms.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Roivant's upcoming earnings report, given its recent performance. The market is looking for continued improvement in EPS and revenue growth.

Bull Case

If Roivant can maintain its trend of beating EPS estimates, it could see a strong positive reaction from investors, reinforcing confidence in its growth strategy.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a negative market reaction, especially given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q1-2026?

The EPS figure is crucial for understanding Roivant's profitability and will heavily influence investor sentiment.

How much has R&D spending increased compared to last quarter?

R&D spending is a key indicator of Roivant's commitment to innovation and future growth potential, making it a focal point for investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Roivant's potential for strong EPS growth based on its recent performance and R&D advancements.

Supporting Evidence

Roivant has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.

The options market is pricing a significant move, suggesting that investors are anticipating volatility that could favor a positive outcome.

Key Risk

If R&D spending shows a marked increase without corresponding revenue growth, it could undermine the bullish consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Roivant's ability to sustain its recent performance, particularly in terms of profitability and growth.

Bull Confirmed If

An EPS of $0.30 or higher would confirm the bullish outlook and suggest strong operational performance.

Bear Confirmed If

An EPS below $0.20 would indicate potential issues with profitability and could confirm the bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±10.0%

Historical Avg

±7.2%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating uncertainty about the earnings outcome.

Options are pricing ±10.0% while ROIV has averaged ±7.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

51.6%

Calls (5K)P/C Ratio: 0.18Puts (1K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Roivant beats expectations, history suggests a potential stock increase of around 9.09%, confirming investor confidence in its growth strategy.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction, reflecting cautious optimism without strong conviction.

Miss

If Roivant misses estimates, the stock could decline, with historical data suggesting an average drop of around 0.73%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of ongoing clinical trials.
2Details on any new partnerships or collaborations.
3Insights into R&D spending and its impact on future growth.
4Management's outlook on market conditions and competition.
5Any changes in guidance or strategic direction.